N-(9-Ethyl-9H-carbazol-3-yl)-2-pyridin-4-yl-acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(9-Ethyl-9H-carbazol-3-yl)-2-pyridin-4-yl-acetamide
• 英文别名: N-(9-ethylcarbazol-3-yl)-2-pyridin-4-ylacetamide
• 化学式: C₂₁H₁₉N₃O
• 分子量: 329.401
• InChiKey: HVAZAKMBBOFOHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吡啶-4-乙酸 、 3-氨基-9-乙基咔唑 在 4-二甲氨基吡啶 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(9-Ethyl-9H-carbazol-3-yl)-2-pyridin-4-yl-acetamide
  参考文献：
  名称：

  Structure–activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres

  摘要：

  Beginning with carbazole la, the amide and alkyl substituents were optimized to maintain potency while adding solubilizing groups. Efforts to replace the 3-amino-9-ethylcarbazole core, a known carcinogen, used the SAR generated in the carbazole series for guidance and led to the synthesis of a number of core-modified analogues. In addition, an isosteric series, in which the amide was replaced with an imidazole, was prepared. Two potent new series lacking the putative toxicophore were identified from these endeavors. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00329-9

文献信息

• US6399631B1
  申请人：——

  公开号：US6399631B1

  公开（公告）日：2002-06-04
• [EN] HEPATITIS C VIRUS ENTRY INHIBITORS<br/>[FR] INHIBITEURS DE LA PÉNÉTRATION DU VIRUS DE L'HÉPATITE C
  申请人：IMMUSOL INC

  公开号：WO2008021745A2

  公开（公告）日：2008-02-21

  [EN] The present invention relates to the use of tricyclic diphenylamine derivative compounds for prevention and/or treatment of Hepatitis C virus (HCV) infection by inhibiting HCV entry into permissive cells.
  [FR] La présente invention concerne l'utilisation de composés dérivés de la diphénylamine tricyclique pour la prévention et/ou le traitement d'une infection par le virus de l'hépatite C (Hepatitis C Virus : HCV) en inhibant la pénétration du HCV dans les cellules permissives.
• Structure–activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres
  作者：Marlys Hammond、Richard L. Elliott、Melissa L. Gillaspy、David C. Hager、Richard F. Hank、Janet A. LaFlamme、Robert M. Oliver、Paul A. DaSilva-Jardine、Ralph W. Stevenson、Christine M. Mack、James V. Cassella

  DOI：10.1016/s0960-894x(03)00329-9

  日期：2003.6

  Beginning with carbazole la, the amide and alkyl substituents were optimized to maintain potency while adding solubilizing groups. Efforts to replace the 3-amino-9-ethylcarbazole core, a known carcinogen, used the SAR generated in the carbazole series for guidance and led to the synthesis of a number of core-modified analogues. In addition, an isosteric series, in which the amide was replaced with an imidazole, was prepared. Two potent new series lacking the putative toxicophore were identified from these endeavors. (C) 2003 Elsevier Science Ltd. All rights reserved.